Race Oncology Ltd. (AU:RAC) has released an update.
Race Oncology Ltd has announced successful non-clinical toxicology and safety studies of its chemotherapeutic drug RC220 bisantrene, revealing an excellent safety profile for peripheral intravenous infusion. The complete results enable the company to proceed with human clinical trials in the second half of 2024 and prepare for a US FDA Investigational New Drug application in 2025. These milestones follow on-budget and on-time completion of studies by Attentive Science and Agilex Biolabs, showcasing Race’s efficiency in the development of new oncology treatments.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.
